Specify Company / Ticker to Get the Summary
Dividend History PRLD
Dividend Analytics PRLD
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Prelude Therapeutics Inc
PRLDPrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Address: 175 Innovation Boulevard, Wilmington, DE, United States, 19805
Analytics
WallStreet Target Price
3.75 USDP/E Ratio
–Dividend Yield
–Financials PRLD
Results | 2019 | Dynamics |